Tag: Immutep
First dose administered in Efti, BAVENCIO trial for metastatic urothelial cancer
Immutep Limited, a pioneering clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced the enrollment and safe dosing of the first patient in the INSIGHT-005 Phase I trial in the fight against metastatic urothelial carcinoma.
Immutep gets green light for large-scale cancer product manufacturing for clinical trials
Immutep Limited, a clinical-stage biotechnology company specialising in LAG-3 immunotherapies for cancer and autoimmune diseases, has received regulatory authorisation for the commercial manufacturing of Eftilagimod Alpha (efti) at a scale of 2,000 litres for clinical trial use.
Featured Article
Unlocking growth: Charting midsize manufacturers’ path with digital solutions
According to a recent study by Oxford Economics, midsized companies in the industrial manufacturing sector are setting their eyes on ambitious growth targets. The research, authored in partnership with SAP, revealed that 38% of industry leaders have identified market expansion as their top priority.
